Last week, tech companies on the Puget Sound made a variety of growth-oriented moves. With new acquisitions and venture capital raises on the scene, find out what’s under way. This is the Built In Seattle weekly refresh.
Microsoft acquired Nuance. The tech giant is planning to further its expansion into the healthcare industry following its second largest acquisition to date. Nuance develops AI-powered products that transcribe info from doctor-patient conversations into a patient’s health records. Microsoft is buying $19.7 billion in stock for the Massachusetts-based company. [Built In Seattle]
Seeq raised $50M. Helping manufacturing sites improve their business is analytics software provider Seeq. Its platform lets users gather data insights from their factories’ connected devices. After a Series C raise, Seeq is planning to fund product development and market expansion. It’s also currently hiring as it looks to build out its development, sales, and marketing resources. [Built In Seattle]
Seattle Tech Quote of the Week
Routable pulled in $30M. The company is planning to grow and scale its team following its Series B raise led by Sam Altman, Y Combinator’s former president. Routable develops software to help simplify the process of companies sending and receiving payments from one another. It’s hiring for 10 roles across teams including product, engineering and marketing. [Built In Seattle]
Glow was acquired by Libsyn. As podcasts continue to grow in popularity as mainstream entertainment, Glow, a startup spun out of Pioneer Square Labs, is helping creators monetize their work. Libsyn acquired the company in a $1.2 million deal and plans to use Glow’s tech, like private feed distribution and subscription billing, across its expansive network of podcasts. [GeekWire]
2Morrow secured $1.5M. Kirkland-based 2Morrow aims to address some of the most prevalent healthcare issues across the country using evidence-based programs that combine tech behavioral science. Following its WRF Capital-led funding round, the startup is planning to grow its platform and expand into digital therapeutics for chronic conditions. [2Morrow]
